{
    "nct_id": "NCT04134325",
    "official_title": "A Prospective Pilot Study Assessing the Immunomodulatory Effect and Clinical Activity of Programmed Cell Death Protein 1 Inhibition Following CD30 Directed Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Classical Hodgkin Lymphoma",
    "inclusion_criteria": "Inclusion Criteria for Arm 1: Relapse After Prior CD 30 CAR-T Therapy\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Age ≥18 years at the time of consent.\n* Subject is planned to start on standard of care anti-PD-1 therapy per community standards of medical care by their treating oncologist.\n* Subject has a diagnosis of relapsed/refractory classical Hodgkin lymphoma after at least three lines of prior therapy with clinical progression after either ATLCAR.CD30 and/or ATLCAR.CD30.CCR4. The CAR-T cell product may be either the UNC, Baylor or Tessa product.\n* Subjects with prior allogeneic stem cell transplant will be eligible but will be counseled during consent regarding possible increased risk of graft versus host disease with anti-PD-1 therapy after allogeneic stem cell transplant.\n* Subjects must have previously been treated with anti-PD-1 therapy (any anti-PD-1 therapy either standard of care or investigational) prior to receiving autologous CAR-T-cell therapy.\n* Subject is willing to provide blood samples that are clinically necessary during anti-PD-1 therapy administered per community standards of medical care.\n\nInclusion Criteria for Arm 2: Relapse with no Prior CD 30 CAR-T Therapy\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Age ≥18 years at the time of consent.\n* Subject is planned to start on standard of care anti-PD-1 therapy per community standards of medical care by their treating oncologist.\n* Subject has a diagnosis of classical Hodgkin lymphoma.\n* Subjects with prior allogeneic stem cell transplant will be eligible but will be counseled during consent regarding possible increased risk of graft versus host disease with anti-PD-1 therapy after allogeneic stem cell transplant.\n* Subject is willing to provide blood samples that are clinically necessary during anti-PD-1 therapy administered per community standards of medical care.\n* Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.\n* Subject is willing to consent to study-required blood draws.\n\nExclusion Criteria for Arm 1: Relapse After Prior CD 30 CAR-T Therapy\n\n* Subject has received anti-CD30 CAR-T therapy within the previous 6 weeks.\n* Subject has known active infection with HIV, HTLV, HBV, HCV or any active, uncontrolled infection or sepsis.\n* Subject has received chemotherapy or anti-PD-1 therapy following CD30 CAR-T cell product administration.\n* Subject has a known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least five years.\n* Subject is currently using systemic corticosteroids at doses ≥10 mg prednisone daily or its equivalent, or other immunosuppressive medications.\n\nExclusion Criteria for Arm 2: Relapse with no Prior CD 30 CAR-T Therapy\n\n* Subject has received anti-CD30 CAR-T therapy\n* Subject is currently using systemic corticosteroids at doses ≥10 mg prednisone daily or its equivalent, or other immunosuppressive medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}